Key result
Short-term intravenous levosimendan reduced the composite of death, myocardial ischemia, or worsening heart failure compared to placebo (43.7% vs 62.5%; HR 0.636; 95% CI 0.413-0.981; p=0.041).
Why the study?
Does short-term intravenous infusion of levosimendan reduce the composite of death, myocardial ischemia, or worsening heart failure in patients with heart failure complicated by acute myocardial infarction?
Population
160 patients with heart failure due to acute myocardial infarction (AMI)
Comparison
Short-term intravenous infusion of levosimendan vs Placebo
Design
RCT, Randomly divided into 2 groups, Single-blind
Follow-up
6 months
Authors
Loading...
Supports levosimendan in AMI-complicated HF; extends RCT evidence to this high-risk acute setting.
RCT (n=160)
Single-blind
randomly divided
No
Does short-term intravenous infusion of levosimendan reduce the composite of death, myocardial ischemia, or worsening heart failure in patients with heart failure complicated by acute myocardial infarction?
Hazard Ratio: 0.636 (95% CI 0.413–0.981)
Absolute Event Rate: 43.7% vs 62.5%
p-value: p=0.041
Short-term intravenous levosimendan significantly reduces the composite of death, myocardial ischemia, or worsening heart failure at 6 months in patients with heart failure complicated by acute myocardial infarction.
Jia et al. (2014) conducted an RCT in Heart failure due to acute myocardial infarction (n=160). Levosimendan vs. Placebo was evaluated on composite outcome of death, myocardial ischemia or worsening heart at the 6 month follow-up (HR 0.636, 95% CI 0.413-0.981, p=0.041). Short-term intravenous levosimendan reduced the composite of death, myocardial ischemia, or worsening heart failure compared to placebo (43.7% vs 62.5%; HR 0.636; 95% CI 0.413-0.981; p=0.041).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: